Label: STRIDEGUARD- fenbendazole paste

  • NDC Code(s): 86244-201-01
  • Packager: YASMEEN GLOBAL TRADERS LLC
  • Category: OTC ANIMAL DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Animal Drug Application

Drug Label Information

Updated September 23, 2026

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Paste 10% (100 mg/g)
    HORSE DEWORMER


    INGREDIENTS:
    Fenbendazole…..10% (100mg/g)

  • DESCRIPTION:

    StrideGuard® (fenbendazole) Paste 10% contains the active anthelmintic, fenbendazole. The chemical name of fenbendazole is methyl 5-(phenylthio)-2-benzimidazole carbamate

    The chemical structure is:

    Chemical Structure

    Chemical Structure

    Each gram of StrideGuard® Paste 10% contains 100 mg of fenbendazole and is flavored with artificial apple-cinnamon liquid.

  • ACTIONS:

    The antiparasitic action of Fenivox® Paste 10% is believed to be due to inhibition of energy metabolism in the parasite.

  • INDICATIONS:

    Fenivox® Paste 10% is indicated for the treatment and control of: Large strongyles (Strongylus edentatus, S. equinus, S. vulgaris) Encysted early 3rd stage (hypobiotic), late 3rd stage and 4th stage cyathostome larvae Small strongyles Pinworms (Oxyuris equi) Ascarids (Parascaris equorum) and for the control of arteritis caused by 4th stage larvae of Strongylus vulgaris in horses.

  • PRECAUTIONS:

    Side effects associated with StrideGuard® Paste 10% could not be established in well-controlled safety studies in horses with single doses as high as 454 mg/lb (1,000 mg/kg) and 15 consecutive daily doses of 22.7 mg/lb (50 mg/kg).Particularly with higher doses, the lethal action of fenbendazole may cause the release of antigens by the dying parasites. This phenomenon may result in either a local or systemic hypersensitivity reaction. As with any drug, these reactions should be treated symptomatically. StrideGuard® Paste 10% has been evaluated for safety in pregnant mares during all stages of gestation with doses as high as 11.4 mg/lb (25 mg/kg) and in stallions with doses as high as 11.4 mg/lb (25 mg/kg). No adverse effects on reproduction were detected. The recommended dose for control of 4th stage Strongylus vulgaris larvae, 4.6 mg/lb (10 mg/kg) daily for 5 consecutive days, has not been evaluated for safety in stallions or pregnant mares.

  • DOSAGE:

    For foals and weanlings (less than 18 months of age) where ascarids are a common problem, the recommended dose is:4.6 mg/lb (10 mg/kg); one syringe will deworm a 550 lb horse, For the control of large strongyles, small strongyles, and pinworms, the recommended dose is:2.3 mg/lb (5 mg/kg).For control of hypobiotic (encysted early 3rd stage), late 3rd stage, and 4th stage cytostome larvae, 4th stage Strongyles vulgaris larvae, the recommended dose is:4.6 mg/lb (10 mg/kg) daily for 5 consecutive days; administer one syringe for each 550 lb body weight per day. Do not under dose. Ensure each animal receives a complete dose based on a current body weight. Under dosing may result in ineffective treatment and encourage the development of parasite resistance.

  • WARNINGS

    WARNINGS: Not for use in humans. Keep this and all drugs out of reach of children. Refrain from smoking or eating while handling. Wash hands after use. Avoid contact with eyes.

  • SPL UNCLASSIFIED SECTION

    OTHER WARNINGS: Do not use in horses intended for human consumption. Parasite resistance may develop to any dewormer, and has been reported for most classes of dewormers. Treatment with a dewormer used in conjunction with parasite management practices appropriate to the geographic area and the animal(s) to be treated may slow the development of parasite resistance. Fecal examinations or other diagnostic tests and parasite management history should be used to determine if the product is appropriate for the herd prior to the use of any dewormer. Following the use of any dewormer, effectiveness of treatment should be monitored (for example, with the use of a fecal egg count reduction test or another appropriate method). A decrease in a drug's effectiveness over time as calculated by fecal egg count reduction tests may indicate the development of resistance to the dewormer administered. Your parasite management plan should be adjusted accordingly based on regular monitoring.

  • DIRECTIONS FOR USE:

    1. Determine the weight of the horse.
    2. Remove syringe tip.
    3. Turn the dial ring until the edge of the ring nearest the tip lines up with the correct weight marking.
    4. Depress plunger to advance paste to tip.
    5. Set the dial ring at the graduation nearest the weight of the horse for the dosage rate of 5 mg/kg. For the dosage rate of 10 mg/kg, set the dial ring at two times (double) the horse’s weight.
    6. Horse’s mouth should be free of food.
    7. Insert nozzle of syringe through the interdental space and deposit the paste on the back of the tongue by depressing the plunger.

      CONSULT YOUR VETERINARIAN FOR ASSISTANCE IN THE DIAGNOSIS, TREATMENT AND CONTROL OF PARASITISM.
  • HOW SUPPLIED:

    Fenivox® Paste 10% Equine Dewormer is supplied in 25 gram syringes.

    Store at 20°–25°C (68°–77°F).

    Protect from excessive heat and freezing.

  • SPL UNCLASSIFIED SECTION

    Distributed by:

    YASMEEN GLOBAL TRADERS LLC
    30 N Gould St Ste 53477
    Sheridan, WY 82801 USA
    Email: Contact@strideguardpet.com
    Website: www.strideguardpet.com

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC 86244-201-01

    Fenivox®

    Fenbendazole
    Equine Dewormer Paste

    25 g (0.88 oz)
    Paste 10% (100 mg/g)

    Broad-Spectrum Parasite Control

    Treats & Controls:
    Large Strongyles, Small Strongyles,
    Ascarids, Pinworms, and Lungworms

    Effective:
    Broad-spectrum internal parasite protection

    Easy to Use:
    Convenient 25 g paste syringe for horses

    Apple Flavor

    FOR ANIMAL USE ONLY
    product label01
    product label02

  • INGREDIENTS AND APPEARANCE
    STRIDEGUARD 
    fenbendazole paste
    Product Information
    Product TypeOTC ANIMAL DRUGItem Code (Source)NDC:86244-201
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    FENBENDAZOLE (UNII: 621BVT9M36) (FENBENDAZOLE - UNII:621BVT9M36) FENBENDAZOLE100 mg  in 1 g
    Product Characteristics
    Color    Score    
    ShapeSize
    FlavorAPPLE, CINNAMONImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:86244-201-011 in 1 CARTON
    125 g in 1 SYRINGE, PLASTIC
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NADANADA12064805/15/2020
    Labeler - YASMEEN GLOBAL TRADERS LLC (140202031)